Member Info for gtc1507

Amazing news yesterday but wasnt expecting that! Sets them up fantastically to progress their R&D with less cost to the business. Meanwhile, they’ve massive other opportunities including :

- partnership with USA national cancer institute

- developed multiple class leading proprietary technologies which could be licensed/bought out

- working with Oxford uni to develop their own AI algorithms

- contracts with leading global diagnostic companies for ongoing supply

- repurposing their tech generating 2-30x yield improvements for clients existing valuable antibody assets

- multiple milestone and royalty interests for antibodies being developed around the world plus the potential for the consortium to massively improve the portfolio they get an interest in.

Overall the future looks bright and can see why the CEO looked so happy in his update video announcing the “major major news”

Innovative medicines institute gets £55m investment https://www.bbc.com/news/articles/c05pgne7d69o

Morning!

Shard capital did a recent analysis note which is quite helpful in their assumptions

https://shardcapital.com/capital-markets/corporate-broking/research-portal/

Hah thanks for clarifying was wondering if I’d missed something exciting! Yes the sharesoc presentation should be good. Interesting they’ve two investor updates so close together wonder are they expecting something in between

Darkryders gone dark about Tuesday! Only thing I’m aware of on the horizon is the sharesoc webinar so any insight would be greatly appreciated

What’s happening next Tuesday?

That should say NCI are putting more resources behind the project

Management confirmed yesterday that NCI work was progressing well, they were putting more resources behind the project but they couldnt give any more information and to bear with them as government agencies can work slowly so we just needed to be patient.

Https://youtu.be/Y7M6zY3wCnw?feature=shared

My mistake I couldn’t count 3 months 🤣🤣🤣.

Interims due by end of December, although historically they’ve always put them out end of November/early Dec.

Whilst we know the top line, it will be great to see the detail underneath particularly with cash/receivables and also see if we get any more forward looking detail.

They have to put the interims out before end of November so must be in the next few weeks

I don’t think he was as definitive as that - he said he didn’t want to say too much at this stage but that publications are part of agreement, they will be coauthored and peer reviewed and they would be targeting high impact journals. He said to bear with them and consider that the peer review process does take some time also to complete. So reading between the lines he didn’t want to give anything away but referred to some important positive reasons that it could take time. We’re a year in and he said they were looking at 4 different targets so you would hope they would be making good progress and we could hear something positive soon!!

Indeed, we’re only 3 weeks out from the CEO buying and a trading statement which told us they’d doubled revenues versus the last years same period, that margins had shot up, that they didn’t need to raise (and the fact the nomad signed this off isn’t insignificant) and that they were on track and on plan to profitability. Let’s not lose sight of the horizon and focus on short term speculation around the cash runway which they already clarified. I suspect we’ll see large figure in trade receivables in the interim accounts which should only be a few weeks away at most that verify they’ve significantly improved their stability, margins and that the cash position is much healthier than we expected.

Plus, news could land any day in relation to Optimal and the USA national cancer institute’s partnership or any of the other exciting strands of work they’re proceeding with.

Https://www.linkedin.com/posts/fusion-antibodies-plc_bioeurope-bioeurope2024-lifesciences-activity-7259141666287075329-q7E2?utm_source=share&utm_medium=member_ios

I imagine their interims will be out by then and a great story to tell.

Their last investor meet company is one of the most bullish I’ve seen from a company. They’re clearly very confident in their prospects and their plans for recovery. Great to see.

Budget was pretty friendly for life sciences and the £520m advanced manufacturing fund announced. Hopefully fab and its clients can secure some of the pie.

Indeed, and at the AGM when the question was posed on the cash position and how the cash position would last that long the CFO confirmed that they were due large accounts receivable at the reporting date so I suspect the cash position is higher and more sustainable than that at 30 September.

About time. The company has a lot going for it and the management have reshaped them to be in a much better place.

Https://x.com/sharesocuk/status/1850858801643049353?s=46

Fab presenting at webinar on 12th December. Suspect H1 results will be published before then.

https://www.sharesoc.org/events/discovery-company-webinar-12-december-500pm/